Overview

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

Status:
Completed

Trial end date:
2020-01-09

Target enrollment:

Participant gender:

Summary

The purpose of study was to test whether rivaroxaban added to standard of care treatment, when compared to placebo, had the potential to reduce the incidence of the clinical events related to the clots and complications of the heart and brain (CV death, MI, or stroke) or the legs (acute limb ischemia or major amputation) in patients who had undergone recent procedure(s) to improve the blood flow of their legs.

Phase:

Phase 3

Details

Lead Sponsor:

Bayer

Collaborators:

Colorado Prevention Center
Janssen Research & Development, LLC

Treatments:

Rivaroxaban